Methods: Based on inclusion and exclusion criteria, 20 patients primarily diagnosed with CUPAx referred to our breast multidisciplinary team (MDT) sessions between July 2010 and December 2016 were evaluated. The patients were categorized into three groups based on the types of treatment: mastectomy and radiation therapy, radiation therapy, and observation group.
very rare case and the incidence rate is reported 2, 3 between 0.12 to 0.67 % of all diagnosed cancers. Some evidences manifest the incidence of CUP involving axillary lymph nodes is between 0.1 and 1 [4] [5] [6] [7] % of all patients with breast cancer. The primary site of CUPAx is most often hidden in the breasts; however lung, ovary, thyroid, pancreas, urogenital tract, or intestines are the other possible primary
Introduction
Cancers of unknown primary (CUPs) are a group of histologically confirmed metastatic cancer of which the primary site is undetectable even after a complete and standard diagnostic and pathologic workups. The incidence rate of CUPs is 3-5% of all 1 solid malignant tumors. The most affected sites were the bones, liver, lungs, and lymph nodes. The CUP involving axillary lymph nodes (CUPAx) is a
The management of the axilla in CUPAx is less controversial. In a review by Pentheherodakis et al., the vast majority of practitioners routinely practiced axillary lymph node dissection (ALND) (level I and II); however, in smaller groups of cases, axillary excisional biopsy and irradiation of the axilla were applied. They reported that in-axilla failure rate after a level I/II ALND (<10%) was lower than excisional 2 biopsy and/or axillary irradiation (20% to 50%).
The records of patients filed in the Breast multidisciplinary team (MDT) sessions (Cancer Institute of Imam Khomeini Hospital) between July 2010 and December 2016 were retrospectively reviewed. The participants signed an informed letter of consent at the time of final follow up. In addition, the ethics committee of the hospital approved this study. Patients with CUPAx entered the study and their hospital charts were reviewed. Different types The present study was an attempt to examine the long-term outcome of CUPAxin patients at Cancer Institute of Imam Khomeini hospital based on patients' characteristics and treatment plans.
Methods
The CUPAx belongs to favorable subsets of CUP which respond to local or systematic treatments with a longer survival term. Some studies have compared the prognosis of patients with CUPAx to early breast cancer patients. Montagna one of the modalities with high sensitivity to detect occult breast cancer in CUPAx patients. Some studies on CUPs have reported that accuracy of fluorodeoxyglucose (FDG) PET ranges from 25% to 9 43%. Figure 1 illustrates the overall survival of all of data were retrieved including: history, physical examination, demographic characteristic, imaging studies (Mammography, Ultrasonography, MRI, and metastatic work up), pathology, IHC results (ER, PR, HER-2, TTF1, CK7, GCDFP15, CK AE1/AE3, and HMB45), and local and systemic therapies.
The patients were categorized according to the local treatment of the breast into three groups: 1mastectomy and radiation therapy, 2-radiation therapy, 3-no local therapy of the breast (observation group). In addition, all patients received chemotherapy.
Patients with incomplete data, primary lesion in the breast imaging, history of breast cancer in contralateral breast, evidence of distant metastasis, other cancers based on histologic results, and IHC of axillary lymph node were excluded. Standard followed up procedure was implemented and the outcome was categorized according to the last follow up. The final outcomes were no evidence of disease (NED), alive with disease (AWD), and dead of disease (DOD).
The collected data was analyzed in SPSS (version 13, Chicago, IL, USA). Categorical variables were expressed in number (%) and continuous variables were represented as mean ± standard deviation. Chisquared test or Fisher's exact test was used to compare categorical variables (P< 0.05). Kaplan-Meier approach was used to estimate the median survival from the time of diagnosis to the time of event (death or alive with disease) and overall survival was compared between treatment groups with a log-rank test.
Breast MDT recommendation to all patients was ALND with systemic therapy before ALND. Either mastectomy and chest wall radiation or whole breast irradiation was recommended as local treatment of the breast. The final treatment would differ depending on patients' priorities and principal physician's decision.
Between July 2010 and December 2016, 20patients with primary diagnosis of CUPAx referred to our breast MDT sessions were selected based on the exclusion and inclusion criteria (n= 20). Four patients had a suspicious lesion in mammography or US. Biopsy of these lesions revealed three fibroadenomas and one cases of usual ductal hyperplasia. Five patients had suspicious lesion on breast MRI, which was detectable on targeted US. The biopsy of these lesions proved to be benign. Lymph node IHC results such as TTF1, CK7, CK 20, GCDFP15, CK AE1/AE3, and HMB45 were in line with breast cancer origin. Table 1 lists the patients' characteristics. The mean age of the affected women was 52 ±7.91 years (range: 42-74) and 55% of them were in postmenopausal status.
Results
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patients who participated in this study. The mean survival time was 57.19 months (95% CI: 44.75-69.64). Table 2 lists the number of patients with different treatments and outcomes. The significant differences between the outcome of three types of treatments are evident. The patients who received both mastectomy and radiotherapy have a higher survival rate and no evidence of disease compared with other groups (P= 0.03). Categorizing the patients into two groups based on mastectomy revealed that 76.9% (10/13) of patients who received mastectomy had no evidence of disease and the complication occurred only in three patients (23.1%). However, 29% (2/7) of patients who did not receive mastectomy were alive without disease and the complication occurred in five patients (71%). This difference is also statistically significant (P= 0.06) (Data not shown in the table). Survival time period comparison with Log Rank test manifested the median survival time of the mastectomy group was 78 months and 23 months for the other group (no mastectomy) (95% CI: 7.64-38.36); the difference is statistically significant (P <0.001).
There was a patient in the mastectomy and irradiation group with follow up of 42 months (total of 13 patients) with regional relapse in axillary lymph node and another patient with liver metastasis. In the irradiation group with follow up of 25 months (total of 4 patients), one patient developed multiple bone metastasis and the other patient died from widespread visceral (ovary & lung) and bone metastasis at 44th month from her first presentation. Finally, in the group without any local treatment with follow up period of 22 months (totally 4 patients), one patient demonstrated local recurrence on the chest wall with ulceration, another one developed cervical lymph node metastasis, and the third patient developed multiple bone metastasis.
The CUPAx is a rare clinical entity and it has been [13] [14] [15] [16] reported in case reports. There are also a few 5, 6 studies with large sample size. Breast is the most likely origin of CUPAx and ER or PR positive in IHC assay of axillary lymph node could support the origin of breast; still, negative results do not exclude the 14 breast origin.
Twenty cases of CUPAx who referred to our cancer institute with the median follow-up of 38 months (range: 14-78) were studied. Interestingly, the mean age of subjects (52 years old) was similar to 2 a large systematic review. The result suggested that mastectomy was effective in lowering the risk of disease progression and as a best modality, it should be recommend to all patients with CUPAx with highly suspicious breast origin Consistent to the present study, Sohn et al.'s investigation showed the overall survival in patients undergoing ALND only, breast conserving surgery, and mastectomy with ALND was not significantly 6 different (P= 0.061). The authors believe that the statistical uncertainty of our result is due to the small sample size. However, Sohn et al. evaluated 142 cases and they reported the same results. Another study with 48 CUPAx cases revealed that the patients with ipsilateral radiotherapy and breast conservation therapy (BCT) or mastectomy had better 5-year local recurrence free survival compared with observation 5 group. They did not evaluate the survival time for m a s t e c t o m y a n d B C T s e p a r a t e l y. T h e y recommended a standard radiotherapy to improve local control in patient with occult primary breast cancer. However, in the present study only one patient died from the disease and she only received radiation therapy. Therefore, we suggest only radiation therapy without considering surgery may be a threat to the patient's health.
Discussion
Another study in 2010 systematically reviewed published CUPAx case series and 24 retrospective studies enrolling 689 patients. Among the total of 446 patients managed with mastectomy, 72% of them histologically showed that the breast was the primary origin. The authors concluded that mastectomy or radiotherapy provided loco-regional disease control in 75% to 85% of cases. The effect of removing an 5. Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 2011;47 (14):2099-106. 6. Sohn G, Son BH, Lee SJ, Kang EY, Jung SH, Cho A m i n i -r e v i e w i n 2 0 1 5 r e c o m m e n d e d radiotherapy and adjuvant chemotherapy afterwards and/or hormone therapy depending on the risk factors for patients with CUPAx. The authors did not 9 suggest mastectomy as an effective treatment. However, according to a survey by the American Society of Breast Surgeons (ASBS) in 2005, 43% of the experts preferred mastectomy, while 37% opted for whole breast radiation, and 20% selected other 17 treatments (including 6% that chose observation).
As shown by the results here and in the other studies, in CUPAx patients, local therapy of breast by mastectomy or radiation therapy is associated with better results in local control, distant metastasis, and overall survival. Larger prospective studies are required to address this question with more certainty.
